AbbVie Expands Board, Appoints New Independent Director

AbbVie ( (ABBV) ) has shared an update.

On May 9, 2025, AbbVie Inc. expanded its Board of Directors from fourteen to fifteen members, appointing Thomas J. Falk as an independent director and member of the Audit Committee. The Board also announced a future reduction to thirteen directors with the retirement of Richard A. Gonzalez and Glenn F. Tilton on July 1, 2025. Additionally, Robert A. Michael was elected to succeed Mr. Gonzalez as Chairman, with a revised compensation package reflecting his new role. During the 2025 Annual Meeting of Stockholders, several key votes were held, including the election of Class I directors and the ratification of Ernst & Young LLP as the independent accounting firm. However, proposals to amend the certificate of incorporation for voting changes were not approved.

The most recent analyst rating on (ABBV) stock is a Buy with a $190.00 price target. To see the full list of analyst forecasts on AbbVie stock, see the ABBV Stock Forecast page.

Spark’s Take on ABBV Stock

According to Spark, TipRanks’ AI Analyst, ABBV is a Outperform.

AbbVie’s stock score reflects strong earnings performance and cash flow management, though concerns about financial leverage and equity stability persist. The technical indicators suggest stability, while high valuation levels raise caution. Positive earnings guidance and leadership changes support a favorable outlook despite competitive challenges.

To see Spark’s full report on ABBV stock, click here.

More about AbbVie

AbbVie Inc. operates in the pharmaceutical industry, focusing on developing and marketing advanced therapies for complex diseases. The company’s primary products include treatments for immunology, oncology, virology, and neuroscience, with a strong market presence in the healthcare sector.

Average Trading Volume: 7,970,477

Technical Sentiment Signal: Strong Buy

Current Market Cap: $335.7B

For an in-depth examination of ABBV stock, go to TipRanks’ Stock Analysis page.